Asati V - Search Results

1

PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.

Asati V, Mahapatra DK, Bharti SK. Asati V, et al. Eur J Med Chem. 2016 Feb 15;109:314-41. doi: 10.1016/j.ejmech.2016.01.012. Epub 2016 Jan 12. Eur J Med Chem. 2016. PMID: 26807863 Review.

2

Thiazolidine-2,4-diones as multi-targeted scaffold in medicinal chemistry: Potential anticancer agents.

Asati V, Mahapatra DK, Bharti SK. Asati V, et al. Eur J Med Chem. 2014 Nov 24;87:814-33. doi: 10.1016/j.ejmech.2014.10.025. Epub 2014 Oct 12. Eur J Med Chem. 2014. PMID: 25440883 Review.

3

Chalcones and their therapeutic targets for the management of diabetes: structural and pharmacological perspectives.

Mahapatra DK, Asati V, Bharti SK. Mahapatra DK, et al. Among authors: asati v. Eur J Med Chem. 2015 Mar 6;92:839-65. doi: 10.1016/j.ejmech.2015.01.051. Epub 2015 Jan 26. Eur J Med Chem. 2015. PMID: 25638569 Review.

4

1,3,4-Oxadiazoles: An emerging scaffold to target growth factors, enzymes and kinases as anticancer agents.

Bajaj S, Asati V, Singh J, Roy PP. Bajaj S, et al. Among authors: asati v. Eur J Med Chem. 2015 Jun 5;97:124-41. doi: 10.1016/j.ejmech.2015.04.051. Epub 2015 Apr 27. Eur J Med Chem. 2015. PMID: 25965776 Review.

5

Anti-cancer chalcones: Structural and molecular target perspectives.

Mahapatra DK, Bharti SK, Asati V. Mahapatra DK, et al. Among authors: asati v. Eur J Med Chem. 2015 Jun 15;98:69-114. doi: 10.1016/j.ejmech.2015.05.004. Epub 2015 May 14. Eur J Med Chem. 2015. PMID: 26005917 Review.

6

Chalcone scaffolds as anti-infective agents: structural and molecular target perspectives.

Mahapatra DK, Bharti SK, Asati V. Mahapatra DK, et al. Among authors: asati v. Eur J Med Chem. 2015 Aug 28;101:496-524. doi: 10.1016/j.ejmech.2015.06.052. Epub 2015 Jul 10. Eur J Med Chem. 2015. PMID: 26188621 Review.

7

Mutant B-Raf Kinase Inhibitors as Anticancer Agents.

Asati V, Bharti SK, Mahapatra DK. Asati V, et al. Anticancer Agents Med Chem. 2016;16(12):1558-1575. doi: 10.2174/1871520616666160606101848. Anticancer Agents Med Chem. 2016. PMID: 27264268 Review.

8

Triggering PIK3CA Mutations in PI3K/Akt/mTOR Axis: Exploration of Newer Inhibitors and Rational Preventive Strategies.

Asati V, Bharti SK, Mahapatra DK, Asati V, Budhwani AK. Asati V, et al. Curr Pharm Des. 2016;22(39):6039-6054. doi: 10.2174/1381612822666160614000053. Curr Pharm Des. 2016. PMID: 27296758 Review.

9

K-Ras and its inhibitors towards personalized cancer treatment: Pharmacological and structural perspectives.

Asati V, Mahapatra DK, Bharti SK. Asati V, et al. Eur J Med Chem. 2017 Jan 5;125:299-314. doi: 10.1016/j.ejmech.2016.09.049. Epub 2016 Sep 16. Eur J Med Chem. 2017. PMID: 27688185 Review.

10

MEK inhibitors in oncology: a patent review (2015-Present).

Mahapatra DK, Asati V, Bharti SK. Mahapatra DK, et al. Among authors: asati v. Expert Opin Ther Pat. 2017 Aug;27(8):887-906. doi: 10.1080/13543776.2017.1339688. Epub 2017 Jun 19. Expert Opin Ther Pat. 2017. PMID: 28594589 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

61 results

Search Page